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CYTOSINE ARABINOSIDE (Ara-C) is a
pyrimidine analogue of deoxycytidine
(CdR) that produces a marked inhibition
of DNA synthesis in replicating cells.
Ara-C is converted intracellularly to the
triphosphate (Ara-CTP) which is a DNA-
polymerase inhibitor that competes with
the normal precursor deoxycytidine tri-
phosphate (dCTP).
Ara-C is one of the most effective drugs
for the chemotherapy of acute myelo-
genous leukaemia (AML) but response to
treatment varies. The patient's clinical
condition and haematological status, to-
gether with the [3H]-TdR labelling index
(LI), may account for some of this varia-
tion (Freireich et al., 1975). Individual
differences of some prognostic value are
found in the pharmacokinetics of Ara-C
(Ho & Frei, 1971) in the rate of its phos-
phorylation to Ara-CTP (Kessel et al.,
1969) and in the rates of deamination of
Ara-C and its monophosphate (Ara-CMP)
(Steuart & Burke, 1971; Tattersall et al.,
1974).
Although intracellular concentrations
of Ara-CTP might be predicted from a
complete knowledge of the details of
Ara-C metabolism, the extent ofinhibition
of DNA synthesis at any particular Ara-
CTP level may also vary between different
types of cell (Chou et al., 1977). We have
therefore compared the uptake of [3H]-
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TdR in vitro, as a measure of DNA syn-
thesis, by normal and AML cells in order
to detect any differences in their sensi-
tivity to Ara-C.
Patients with AML were studied at
diagnosis (new AML, 14) in remission (5)
or in relapse (5) and had received no
chemotherapy for at least 3 weeks.
Marrow aspirates were passed through
26-gauge needles into tubes containing
3 ml medium (Eagle's MEM with Hanks'
salts; Flow, U.K.), 1 ml dextran 110 (6%
in 0.900 saline) and 200 u preservative-
free heparin, and were allowed to settle at
room temperature. After 15-30 min the
supernatant was centrifuged at 500 revs/
min for 5 min; the cells were resuspended
in fresh medium and passed through a
stainless-steel mesh (36dm apertures).
Normal marrow was obtained from ribs
taken from patients with non-invasive
carcinoma ofthe bronchus or with cardiac
conditions.
Between 2 x 105 and 1 x 106 cells were
used in duplicate or triplicate 1 lml incu-
bations at 37°C containing 5,tCi methyl-
[3H]-TdR (sp.act. 50-55 Ci/mmol; Radio-
chemical Centre, Amersham, U.K.) and
differing concentrations of Ara-C (Upjohn,
Kalamazoo, Michigan). [3H]-TdR incor-
poration was stopped after 30 min by
adding 041 ml of 0 15M TdR. After one
wash in medium, the cells were lysed withC. G. POTTER AND C. BUNCH
deionized water and precipitated by 5°%
trichloracetic acid (TCA) at 40C. The pre-
cipitate was collected on Millipore filters
(0.45 ,um), washed with 5% TCA followed
by propan-2-ol. Filters were dissolved in
0 3 ml acetone and the released pre-
cipitate was suspended in 11b5 ml Aquasol
(New England Nuclear, Dreiechenhain,
W. Germany) and gelled with 3-5 ml
water. Samples were counted for 100 min
or to 40,000 counts. Channel-ratio quench
correction was used, and efficiencies
ranged from 14 to 22%.
Cells from parallel incubations without
Ara-C were washed and fixed with 3 parts
methanol to 1 part glacial acetic acid.
Slides were made by an air-drying tech-
nique and stained with aceto-orcein.
Autoradiographs were prepared using
ARIO stripping film (Kodak) and exposed
at 4°C for 5 days. After processing, the LI
was determined as the percentage of cells
labelled ( > 5 grains) from samples of 1000
cells.
[3H]-TdR uptake at each point on the
dose-response curves were compared be-
tween patient groups, using Student's t
test. Further statistical comparisons were
facilitated by fitting cubic curves to each
set of data, using a least-squares method.
Variances were stabilized by conversion
of uptake data to log 00 of controls, and
goodness offit was determined by analysis
of variance. Poor fit was generally due to
distortion by terminal values on the
plateau portions of the curve. Removal of
one or two sets ofvalues without encroach-
ing on the sloped portions of the curves
allowed good fit to be obtained. Cubic
curves were considered particularly suit-
able for the present data, as some dose-
response curves showed reversal at the
highest and lowest Ara-C concentrations.
No significant differences were found
between the percentage [3H]-TdR uptake
of normal and remission marrows at each
Ara-C concentration (Fig. 1). A difference
in variance at 1 ,uM (005>P>0 02) was
considered acceptable when pooling nor-
mal and remission data.
Dose-response curves for 14 patients
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FIG. 1. Inlhibition by Ara-C of [3H]TclR
uptake into marrow cells from normal
ribs (0) and patients witlh AML in remis-
sion (LII).
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FIG. 2. Inhibition by Ara-C of [3H]TdR
uptake into marrow cells of patients with
AML at presentation (0) an(l at relapse
( ).
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with AML at presentation (new AML) and
5 in relapse are shown in Fig. 2. [3H]-TdR
uptake in relapse marrow was less in-
hibited than in new AML marrow at 10 nm
and 100 LM Ara-C (both 0 05>P>0 02).
Relapse marrows were less inhibited than
normal or remission marrows by 100 ltM
Ara-C (P<0-001).
New AML marrows were significantly
more inhibited than pooled normal and
remission marrows at 10 nM (0.05>P>
0.02) and 100 nM (P<0 001) whilst at
100 )uM the variance of new AML was
greater (P < 0 002). A similar pattern was
found when rib and remission data were
tested separately. Thus the preliminary
analysis shows that there is considerable
variation of [3H]-TdR uptake at 100 ,uM
Ara-C, whilst at 10-100 nm the new AMLs
are on average more inhibited than normal
marrows.
Figs 1 and 2 show that in some marrows,
especially in the normal and relapse
groups, [3H]-TdR uptake exceeds control
levels at low Ara-C concentrations. This
might be expected in some samples, since
the final percentage is affected by varia-
tion in both experimental and control
levels of [3H]-TdR uptake. However, the
number of measurements at 100 pM or
1 nM that were significantly different from
control levels were no more than would be
expected from the number of t tests. To
minimize this variability, cubic curves
were fitted, the maxima were calculated
and the data normalized to these values.
Data were omitted from one new AML
patients in whom [3H]-TdR uptake was
not measured below 10 nm or at 100 um.
The best fit to one set of rib data had
significant departure from regression
(0.05 >P> 0.02) but was not excluded
since one such departure could be expected
in the fitting of 36 curves.
Calculated inhibition values for Ara-C
concentrations between 10 nm and 100 /M
were compared between patient groups.
Rib and remission data were now indis-
tinguishable, as were new AML and
relapse marrow data. Comparison of the
16 pooled normal and pooled AML groups
showed a greater inhibition of AML at
10 nM and 100 nM (both 0 01 >P>0 005)
whilst at 100 ,iM normal marrow was more
inhibited (0 05 >P> 002). Variances at
10 nm and 100 VM were significanttly
greater in AML than in normal marrow
data (0.02 >P> 0 002).
Normal and remission marrows had a
similar LI (pooled mean 11.2%, s.d.
2.9%). The LI of pooled AML marrow
(mean 8 2%) was not significantly different
from normal marrow, although the varia-
tion was greater (s.d. 7.2%, range 1.0-
32*6%). The LI in each group of marrows
was not significantly correlated with the
inhibition of [3H]-TdR uptake at any part
of the Ara-C dose-response curves.
Inhibition of [3H]-TdR (and 3H-deoxy-
uridine) uptake by normal and leukaemic
cells incubated for 4 h with Ara-C has
been previously described (Wilmanns,
1971) but full dose-response curves were
not obtained in the few patients studied.
In another study leukaemic cells were pre-
incubated with 4 Hm Ara-C before addition
of [14C]-TdR or 3H-uridine, and inhibition
was positively correlated with prognosis
for remission (Zittoun et al., 1975).
In the present study, AML cells were on
average more sensitive to Ara-C at low
concentrations and exhibited greater
variation than normal marrow, although
there was some overlap in sensitivity. The
rates of cellular deamination and phos-
phorylation of Ara-C and its derivatives
differ between patients with AML (Chab-
ner et al., 1974; Coleman et al., 1975). They
also vary with the stage of treatment
(Chou et al., 1977) and have some correla-
tion with subsequent attainment of re-
mission (Steuart & Burke, 1971; Tatter-
sall et al., 1974). Variation of Ara-CTP
levels in AML cells might account for the
differences we have observed in inhibition
of [3H]-TdR uptake.
AML cells were less sensitive than
normal marrow to 100 jLM Ara-C, in con-
trast to the previously reported studies,
but this difference is unlikely to have
clinical value as the levels ofinhibition are
similar (95.48°, in relapses vs 96150% in
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new AML and 96.72% in pooled controls).
Furthermore, 100 tM Ara-C is seldom
reached in the plasma of patients given a
standard 2mg/kg i.v. bolus dose, even at
peak values (Ho & Frei, 1971).
AML cells differ widely in their cell-
kinetic parameters (Skipper & Perry,
1970), and this might be related to the
sensitivity to Ara-C. However, there was
no correlation between the LI or the
absolute uptake of [3H]-TdR in controls
and the sensitivity of any group to Ara-C.
Our experiments were performed with
cells incubated for 30 min with fixed con-
centrations of Ara-C, which is analogous
to the administration of short infusions
in vivo. The patients were treated with
intermittent boluses of Ara-C together
with daunorubicin, so it is not surprising
that cell sensitivity to Ara-C was not
correlated with subsequent remission. It
is possible that the observed in vitro
differential effect of 10-100 nM Ara-C
might be evident in patients given Ara-C
in the form of continuous low-dose in-
fusions. Our preliminary experience with
such infusions, at doses based on the in-
dividual's clearance of Ara-C and the in
vitro sensitivity of their cells, has been
encouraging and clinical studies are in
progress.
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